Shifting patients from a soon-to-go-off-patent blockbuster to its tweaked successor is old hat in the pharma biz. Ever since drugmakers figured out that adding a time-release coating or other slight improvement could earn it a new round of patent protection, they’ve been developing strategies for competing against their own…
Amgen is building up its case for broader use of Vectibix . Ironically, it’s doing so by narrowing its focus
Hamburg Outlines New Approach–Law Enforcement The below, from todays WashPost, will be welcome news to most people here. ****************************************************************************** FDA Poised for More Aggressive Approach By Lyndsey LaytonWashington Post Staff WriterThursday, August 6, 2009 4:05 PM Margaret A. Hamburg, commissioner of the Food and Drug Administration, said Thursday that…
President Bill Clinton announced two important and complementary agreements today to enable better, more affordable treatments for patients on second-line antiretroviral (ARV) therapy for HIV/AIDS in the developing world. For the first time, a second-line regimen of four ARVs will be available for under $500 annually.
Original Source of President…
Think about this: Government agencies and universities research diseases and come up with innovative medicines and treatments in parallel to the private research from the pharmaceutical industry. The drugs and innovations are then negotiated over to for profit business, i.e. the pharmaceutical industry, who expertly mass produce them and bring…
Eli Lilly and Company (NYSE: LLY) and Daiichi Sankyo, Inc. have announced that Effient(TM) (prasugrel), a new antiplatelet medicine, is now available in pharmacies across the United States. The U.S. Food and Drug Administration approved Effient tablets on July 10 for the reduction of thrombotic cardiovascular events (including stent thrombosis)…
26-27th January 2010, Radisson BLU Scandinavia Hotel, Dusseldorf, Germany. With increasing generic competition, challenging molecules coming through discovery and continual pressure to produce cost-effective drugs, companies are increasingly turning to formulation and delivery to secure the success of current and new drug products.
Original Source of World Drug Delivery and…
Amgen (Nasdaq: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) announcement regarding the results of a safety review of Tumor Necrosis Factor (TNF) blockers [marketed as Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol) and…
Wyeth’s Hired Hands As James notes in the thread below, there is an unusually detailed article in today’s NYT about the extent of ghost-written articles used to promote the use of Prempro, including numerous meta-analyses, etc. Nothing new about ghostwriting. But what seems unusual (but may not be) here…
On the 22nd July, the company confirmed that it had contracts in place to supply 195 million doses of its pandemic (H1N1) 2009 adjuvanted influenza vaccine and had a variety of agreements in place with the US Government to supply pandemic products worth $250 million. Since that date, nine government…